Approval · Notice of Compliance 16119 · 2014
ESOMEPRAZOLE: Notice of Compliance 16119
Issued September 18, 2014
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 16119
- Date
- September 18, 2014
- Company
- Sanis Health Inc.Brampton, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Licensing agreement between two companies
- Therapeutic class
- H+,K+-atpase inhibitor
- Canadian reference product
- NEXIUM (Astrazeneca Canada Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ESOMEPRAZOLE | 02431173 | Dormant |
Medicinal ingredients
- ESOMEPRAZOLE MAGNESIUM 40 MG per TAB